<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88964">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813552</url>
  </required_header>
  <id_info>
    <org_study_id>IDX-06A-006</org_study_id>
    <nct_id>NCT01813552</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of IDX719 in Healthy Subjects</brief_title>
  <official_title>Phase I, Randomized, Open-label Study to Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of IDX719 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idenix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idenix Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or
      omeprazole (Prilosec®) on the pharmacokinetics of IDX719 and to assess the safety and
      tolerability of the study drugs when administered alone and in combination in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Up to 17 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pharmacokinetic parameters of plasma drug exposure (AUC0-t, AUCss, Cmax and Ctrough) of IDX719 and ritonavir (RTV) under fasted and fed conditions
Pharmacokinetic parameters  of plasma drug exposure (AUC0-t, AUCss, Cmax and Ctrough) of IDX719 and omeprazole (OMZ) under fasted conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 17 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- Safety and tolerability of IDX719 and RTV or OMZ, alone and in combination, using key safety parameters (adverse events, physical examinations, vital signs, ECGs and standard laboratory safety tests).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1, 9 and 13: Healthy Volunteers will take IDX719 in the mornings under fed or fasted conditions.
Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1, 9 and 13: Healthy Volunteers will take IDX719 in the mornings under fasted conditions.
Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX719</intervention_name>
    <description>IDX719 150 mg tablets (50mg x 3), single dose</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>40 mg delayed-release capsules, once daily</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100 mg tablets, once daily</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read and signed the written informed consent form (ICF) after the nature of the study
             has been fully explained.

          -  All subjects of childbearing potential must have agreed to use a double method of
             birth control (one of which must be a barrier) from Screening through at least 90
             days after the last dose of the study drug.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>80837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>antiviral drugs</keyword>
  <keyword>liver</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
